{
  "docId": "019de073-ce1e-74cc-9870-b1827d8467a5",
  "docSlug": "ce894072ac0bdbdb4be0c6e520599e56",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 31 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 31,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The chart displays a log-scale y-axis for concentration. The data supports once-daily (QD) dosing based on a 20h half-life.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ce1e-74cc-9870-b1827d8467a5/15",
  "deckHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5",
  "deckJsonHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5.json",
  "deckAnchorHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.07,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Pharmacokinetic concentration over time for 25, 50, 75, and 100 mg QD cohorts",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31bf424c-7815-4e11-9ddb-d5b61c08d67f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Data as of 13 Sep 22, for patients treated by 01 Sep 2022. Pharmacokinetic data for 125 mg QD cohort are not shown due to immaturity. CNS, central nervous system; h, hours; PK, pharmacokinetics; QD, once daily; SD, standard deviation.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60e281d9-3d95-4569-93cf-bd8eb15d687c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.35,
        "x": 0.58,
        "y": 0.34
      },
      "kind": "list",
      "text": "NVL-520 exposure exceeded target levels that provide regression in preclinical models. Favorable pharmacokinetics: Low intra-cohort patient PK variability, Exposure increasing with increasing dose level, Half-life of approximately 20h supports QD dosing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aefef54b-99fc-4bd7-b4dc-b09fc2e2c89e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.86,
        "x": 0.07,
        "y": 0.16
      },
      "kind": "title",
      "text": "Pharmacokinetics | NVL-520 Exposure Exceeded Predicted Efficacy Thresholds",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba734d1a-618e-4d6b-823e-7b333c0183f0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "598f5a11-61e4-44ed-bf55-23b40b50634b",
      "evidence": "chart/line: Pharmacokinetic concentration over time for 25, 50, 75, and 100 mg QD cohorts",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 16,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b01545f0-fd92-41f4-970e-28b5cb49def6",
      "evidence": "Slides 6-16 discuss the limitations of current treatments and the potential benefits of Nuvalent's therapies.",
      "position": 0,
      "objective": "What is the cost of not developing effective treatments for cancer patients with specific genetic mutations?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}